• About us
• Contact

Advertisement

Organisation › Details

Catalym GmbH

CatalYm is pioneering a novel immuno-oncology therapy, that safely overcomes GDF-15-mediated immunosuppression in the tumor microenvironment. Our lead product visugromab, a first-in-class GDF-15 neutralizing antibody, has demonstrated potent and durable anti-tumor efficacy with multiple, long-lasting objective responses in combination with anti-PD-1 treatment in phase 1/2 studies in advanced cancer patients. CatalYm is focused on maximizing visugromab’s potential as a new class of cancer immunotherapy with a clinically distinct profile in a range of solid tumor indications. *

 

	Start	2016-08-03 established
	Predecessor	University of Würzburg
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	visugromab (CTL-002)
	Person	L’Huillier, Phil (Catalym 202105– CEO before MSD Europe + Cancer Research Technology + BioFocus Discovery)
	Person 2	Burger, Anne (MedVenture Partners 2002– Director + Breath Therapeutics 201609– CFO + Curetis 201007–2012 CFO)
	Region	München (Munich)
	Country	Germany
	Street	19 Am Klopferspitz
	City	82152 Martinsried
	Tel	+49-89-2000-664-40
		Address record changed: 2024-07-14
Basic data	Employees	n. a.
		* Document for »About Section«: Catalym GmbH. (1/9/24). "Press Release: Catalym Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists". Mainz.
		Record changed: 2024-12-29

Advertisement

More documents for Catalym GmbH

• [1] Catalym GmbH. (7/16/24). "Press Release: Catalym Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab". Munich....
• [2] Catalym GmbH. (1/9/24). "Press Release: Catalym Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists". Mainz....
• [3] Thermosome GmbH. (12/5/23). "Press Release: Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board". Munich....
• [4] Catalym GmbH. (11/22/22). "Press Release: Catalym Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors". Oxford....
• [5] Catalym GmbH. (9/26/22). "Press Release: Catalym Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U.S.". Munich....
• [6] Catalym GmbH. (5/4/21). "Press Release: Catalym Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer". Munich....
• [7] Catalym GmbH. (1/28/21). "Press Release: Catalym Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer". Munich....
• [8] Catalym GmbH. (11/10/20). "Press Release: Catalym Raises EUR50 Million to Advance GDF-15 Antibody into Clinical Trials for Checkpoint-inhibitor Refractory Patients". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.